BHC.TO - Bausch Health Companies Inc.

Toronto - Toronto Delayed Price. Currency in CAD
33.74
-0.24 (-0.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close33.98
Open33.63
Bid33.62 x 0
Ask33.79 x 0
Day's Range33.41 - 33.90
52 Week Range23.60 - 36.52
Volume575,868
Avg. Volume896,322
Market Cap11.758B
Beta (3Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-4.61
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est23.55
  • TheStreet.com11 days ago

    Bausch Health: Long-Term Promise or Stalled at the Top of the Range?

    In his second "Executive Decision" segment of his popular Mad Money program Thursday night, Jim Cramer sat down with Joe Papa, chairman and CEO of Bausch Health Cos. Papa started off by stating that it's the first anniversary of Lumify, BHC's newest treatment for red eyes, and already the product is among the most recommended by doctors and is selling at a $50 million annual run rate. Papa noted that BHC's strength comes from its diversification.

  • BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1
    Market Realist11 days ago

    BHC’s Salix Segment: Xifaxan Drove Its Revenues in Q1

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Salix segment performanceIn the first quarter, Bausch Health Companies (BHC) reported revenues of $445 million for its Salix segment—a rise of 5% YoY

  • PR Newswire11 days ago

    Bausch Health Announces Pricing Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of 7.000% senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of 7.250% senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). The 2028 Notes will be sold to investors at a price of 100.00% of the principal amount thereof and the 2029 Notes will be sold to investors at a price of 100.00% of the principal amount thereof. Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes"), pursuant to its previously announced tender offers, and to pay related fees and expenses.

  • What’s BHC’s Major Revenue Driver in Fiscal 2019?
    Market Realist11 days ago

    What’s BHC’s Major Revenue Driver in Fiscal 2019?

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Bausch + Lomb/International segmentIn the first quarter, Bausch Health Companies (BHC) reported combined YoY (year-over-year) organic revenue growth of 7% for

  • Bausch Health Companies’ Cash Flow Guidance in Fiscal 2019
    Market Realist12 days ago

    Bausch Health Companies’ Cash Flow Guidance in Fiscal 2019

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Cash flow guidanceIn the first-quarter earnings investor presentation, Bausch Health Companies (BHC) has guided for CFO (cash flow from operations) of $1.5

  • PR Newswire12 days ago

    Bausch Health Commences Cash Tender Offers For Up To $1,500,000,000 Aggregate Principal Amount Of Outstanding Notes Of Certain Series

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • PR Newswire12 days ago

    Bausch Health Announces Launch Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes") pursuant to tender offers announced today, and to pay related fees and expenses.

  • Bausch Health Companies Reiterated Its Expense Guidance
    Market Realist12 days ago

    Bausch Health Companies Reiterated Its Expense Guidance

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Expense guidanceIn the first-quarter earnings investor presentation, Bausch Health Companies (BHC) reiterated its adjusted SG&A (selling, general, and

  • Bausch Health Companies Raised Its Earnings Guidance
    Market Realist12 days ago

    Bausch Health Companies Raised Its Earnings Guidance

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)EBITDA guidanceIn the first-quarter earnings investor presentation, Bausch Health Companies (BHC) raised its fiscal 2019 adjusted EBITDA guidance from $3.35

  • BHC: Higher Revenue Guidance for Fiscal 2019
    Market Realist12 days ago

    BHC: Higher Revenue Guidance for Fiscal 2019

    Bausch Health Companies: An Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidanceIn the first-quarter earnings investor presentation, Bausch Health Companies (BHC) raised its fiscal 2019 revenue guidance from $8.30

  • BHC: Analysts’ Recommendations after Q1 Results
    Market Realist12 days ago

    BHC: Analysts’ Recommendations after Q1 Results

    Bausch Health Companies: An Attractive Pick after Q1 Results?Share price movementsOn May 6, Bausch Health Companies (BHC) reported its first-quarter results. The company reported revenues of $2.02 billion in the first quarter—a rise of 1.05% YoY

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Bausch Health Companies Inc.

    Bausch Health Companies Inc NYSE:BHCView full report here! Summary * Perception of the company's creditworthiness is positive and improving * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BHC with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BHC. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $886 million over the last one-month into ETFs that hold BHC are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator with a strengthening bias over the past 1-month. BHC credit default swap spreads are decreasing and near the lowest level of the last three years, which indicates improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Bausch Health Companies, Aquantia, and Athenex Jumped Today
    Motley Fool14 days ago

    Why Bausch Health Companies, Aquantia, and Athenex Jumped Today

    Despite pressure on the broader market, these stocks bucked the downtrend.

  • Bausch Health Companies Inc. (BHC) Q1 2019 Earnings Call Transcript
    Motley Fool14 days ago

    Bausch Health Companies Inc. (BHC) Q1 2019 Earnings Call Transcript

    BHC earnings call for the period ending March 31, 2019.

  • Drug Giant Reports Mixed First Quarter, But Raises Sales Outlook
    Investor's Business Daily14 days ago

    Drug Giant Reports Mixed First Quarter, But Raises Sales Outlook

    Bausch earnings of $1.03 per share, adjusted, topped estimates Monday, but revenue came in light. Bausch Health Companies raised its 2019 sales guidance, though, and Bausch stock rose.

  • Bausch Health Companies Posts Strongest Organic Growth in 3 Years
    Motley Fool14 days ago

    Bausch Health Companies Posts Strongest Organic Growth in 3 Years

    Rising sales in its eye-care segment propelled the drugmaker to its best quarter since 2015.

  • CNBC14 days ago

    Stocks making the biggest moves midday: Bausch Health, Anadarko Petroleum, Nvidia & more

    These are the stocks posting the largest moves midday Monday.

  • Valeant’s Ugly Past Recedes for Its Successor Bausch
    Bloomberg14 days ago

    Valeant’s Ugly Past Recedes for Its Successor Bausch

    Bausch Health Cos Inc. — the business formerly known as Valeant Pharmaceuticals — reported earnings results Monday that were a step forward in its long-promised turnaround under new management. Bausch posted its first quarter of year-over-year revenue growth since 2016 and raised its full year guidance. Bausch wants investors to believe that the days of big negative surprises, guidance cuts, and double-digit sales declines are safely in the past.

  • TheStreet.com14 days ago

    Bausch Health Rises After Trimming Loss, Raising Guidance

    The company, the former Valeant Pharmaceuticals, reported a loss of $52 million, or 15 cents per share, after posting a loss of $2.581 billion, or $7.36 per share, in the year-ago quarter. Revenue for the period rose 1% to $2.016 billion, which was below FactSet's consensus estimate of $2.029 billion. Shares were rising, however, after Bausch Health raised its full-year revenue guidance to between $8.35 billion and $8.55 billion from between $8.3 billion and $8.5 billion.

  • Barrons.com14 days ago

    Bausch Health Stock Jumps as Earnings Help Put the Past in the Past

    Valeant Pharmaceuticals changed its name to Bausch last year, in part to distance itself from its tumultuous past, which included both hits and misses, as well as big stock swings as the company executed its turnaround.

  • Associated Press15 days ago

    Bausch: 1Q Earnings Snapshot

    On a per-share basis, the Laval, Quebec-based company said it had a loss of 15 cents. Earnings, adjusted for non-recurring costs, were $1.03 per share. The results exceeded Wall Street expectations. The ...

  • CNBC15 days ago

    Bausch Health, formerly known as Valeant Pharmaceuticals, shares jump after raising 2019 outlook

    Bausch Health, formerly known as Valeant Pharmaceuticals, is slated to report first-quarter earnings before Wall Street's open on Monday.

  • CNBC15 days ago

    Bausch Health shares jump after the company, formerly Valeant Pharmaceuticals, raises 2019 outlook

    Bausch Health raises its full-year revenues to a range of $8.35 billion and $8.55 billion. It raises its full-year earnings to a range of $3.4 billion and $3.55 billion. It says it also narrowed its quarterly loss to $52 million from a loss of $2.58 billion a year earlier.

  • Bausch Health CEO: Most of our medicines aren't subject to U.S. drug regulations
    CNBC Videos11 days ago

    Bausch Health CEO: Most of our medicines aren't subject to U.S. drug regulations

    Jim Cramer chats with Bausch Health CEO Joe Papa about the company's turnaround and how it's affected by drug pricing.

  • Bausch Health sheds light on Valeant's troubled past
    Yahoo Finance Video14 days ago

    Bausch Health sheds light on Valeant's troubled past

    It's been a little less than a year since Valeant pharmaceuticals became Bausch Health. It also raised its full-year profit forecast today, showing it's throwing off the legacy of its scandal-ridden predecessor. Yahoo Finance's Adam Shapiro and Julie Hyman discuss with panel.